• Clinton Lewis

    Executive Vice President and President, International Operations

Clint Lewis is executive vice president and president of International Operations at Zoetis. In this role, he oversees the management of the livestock and companion animal business markets outside the United States.
Mr. Lewis previously served as president, U.S. Operations at Zoetis and in the Pfizer Animal Health organization. He joined Pfizer Animal Health in 2007.

Mr. Lewis joined Pfizer in 1988 as a sales representative in Long Island, N.Y., and has held positions of increasing responsibility in several areas across various commercial operations dedicated to human health prior to joining animal health, including vice president and general manager of Pfizer’s U.S. Anti-Infectives/HIV business unit.

In 2011, Mr. Lewis was elected chairman of the Animal Health Institute (AHI) for the 2011-12 term. A member of AHI since 2007, Mr. Lewis previously served as AHI vice chair for the 2009-2010 term. AHI is the trade association for the animal health industry in the U.S. advocating on various issues important to the industry, including efficient and effective regulatory and approval processes by the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA), and the Environmental Protection Agency (EPA).

Mr. Lewis holds a bachelor’s degree in biology from Fairfield University and a Master of Business Administration in marketing from Fairleigh Dickinson University.

  • Joachim Hasenmaier

    Head of the Boehringer Ingelheim Animal Health Business Unit and Member of the Boehringer Ingelheim Board of Managing
    Boehringer Ingelheim

Joachim Hasenmaier, born 1960 in Vaihingen/Enz, Germany, DVM., is Member of the Board of Managing Directors of C.H. Boehringer Sohn AG & Co. KG since October 1, 2012, responsible for the Corporate Board Division Consumer Health Care and Animal Health. His nationality is German.

He received a veterinary medical degree (DVM) in 1986 from Ludwig-Maximilians-University, Munich, where he entered into a microbiological research program until 1989 receiving his Doktor med. vet. (PhD) degree. He completed his education with a Master in Management from Kellogg Business School, Chicago, USA in 1991. Prior to joining BI he worked in various positions for various international companies in Germany, Japan, Mexico and Brazil.

In 2002 he joined Boehringer Ingeheim as Corporate Senior Vice President for Boehringer Ingelheim Animal Health. In 2011 he took over the regional responsibilty for Prescription Medicine in NECAR (UK/Ireland, Nordics, Benelux, Canada, Australia/New Zealand). He held this position until he became Member of the Board of Managing Directors at C.H. Boehringer Sohn AG & Co. KG in October 2012.

Jean-Luc Michel
  • Jean-Luc Michel

    Head of Global Strategic Business Unit Companion Animals, Animal Health Business Unit
    Boehringer Ingelheim Animal Health

Dr. Jean-Luc Michel serves as Head of Global Strategic Business Unit Companion Animals, Animal Health Business Unit for Boehringer Ingelheim Animal Health and has 25 years of experience in the Pharmaceutical industry, including 10 years in the Consumer Healthcare markets and nutrition (Monsanto, Johnson & Johnson, and Merck & Co). As Merial’s Chief Commercial Officer, he is responsible for all Global Business Units, Analytics & Market Intelligence, Business Development, Strategic Planning and Commercial Development.

During his tenure at Merial, Dr. Michel has served as Marketing Director for both the Companion Animal and Production Animal businesses in EMEA, Executive Marketing Director for the US Pet Business, and also Head of the Global Pet Vet Business Unit. He was instrumental in redesigning Merial’s state of the art Pet Parasiticides strategy and was key in the launches of FRONTLINE COMBO in the European region and NEXGARD in the United States. He is a member of Merial’s Executive Committee (EXCOM) and the Merial Leadership Team (MLT), groups that steer the course of the company in the short and long term.

Dr. Michel holds an MBA in Finance and Marketing, as well as a Doctorate in Pharmacy. He and his family have lived in Duluth, Georgia for the past three years and will be relocating to Lyon, France in June, 2016.

Dirk - Headshot
  • Dirk Ehle

    Division Head
    Bayer Animal Health

Dr. Dirk Ehle has been a member of the Bayer HealthCare Executive Committee and responsible for the Animal Health Division since May 1, 2012.

Dirk Ehle was born on May 26, 1969, in Cologne, Germany. He studied law at the universities of Freiburg, Aix-en-Provence (France), Wurzburg, and New York (USA).

After three years in law firms, Dirk Ehle started his career at Bayer in 2001 in the Law Department of Bayer HealthCare. In 2006, Ehle transferred to Bayer AG’s Corporate Office where he worked as Executive Assistant to the Chairman of the Board of Management. He was also in charge of Corporate Policy & Advocacy as of 2008. In 2010, Ehle was appointed Senior Bayer Representative for Central Eastern Europe and Bayer HealthCare Representative for Poland.

Dirk Ehle is married with three children.

Jishu_Shi_Photo v2
  • Jishu Shi

    U.S.-China Centre for Animal Health

Dr. Jishu Shi, Professor of Vaccine Immunology, is the director of U.S.-China Center for Animal Health at Kansas State University. Dr. Shi is devoted to advance veterinary education and industry standards in China and around the world. He was instrumental in establishing the Kansas State University and China Scholarship Council Joint Doctor of Veterinary Medicine (DVM) Program that will train 50 Chinese students in the next 10 years through American Veterinary Medical Association-accredited DVM programs in the U.S. For the first time in 63 years since 1950, students from China are being supported ($14 million for 50 students) by their home country to earn a DVM degree from the United States. As the Special Assistant to the Provost for China Affairs at Kansas State University, Dr. Shi worked with Chinese government and universities to set up a Confucius Institute at Kansas State University (CI-KSU) in 2015. CI-KSU is the 102rd CI in the U.S. and has a special focus on agriculture security, public health, and animal health.

Dr. Shi teaches veterinary physiology to the first year students at the College of Veterinary Medicine at Kansas State University. He is the author of more than 100 publications in refereed journals, conference proceedings and book chapters. Dr. Shi’s research programs focus on the development of vaccines for high consequence animal diseases such as classical swine fever (CSF) and porcine reproductive and respiratory syndrome (PRRS).

Having worked at Chinese Academy of Agricultural Sciences, Pfizer, and multiple academic institutions in the U.S. in the last three decades, Dr. Shi is a frequent consultant to animal health companies in the U.S., China, Japan, and Europe. In 2010, Dr. Shi founded VaxiAm Group, a global consulting firm with offices in Beijing and Kansas that focus exclusively on the Chinese animal health market. VaxiAm Group builds bridges between research labs and commercial entities in the U.S. and China and transforms innovative ideas to successful products. In addition, VaxiAm Group provides following services to its clients: investment due diligence, market analysis, regulatory affairs consultation, product registration, and selection of business partners including sales agents, distributors, product co-developers, and manufacturers.

Please see following web links for additional information about Dr. Jishu Shi:

Contact info:; Tel: 785-477-6977

George Gunn - Stonehaven
  • George Gunn

    Founder & CEO
    Stonehaven Consulting

George Gunn has recently retired from his role on the Executive Committee of Novartis AG. He has previously held leadership roles in Johnson and Johnson and Pharmacia and prior to his thirty-two years in the Pharmaceutical Industry he worked for nine years as a veterinarian having graduated from the Royal Dick School of Veterinary Studies in 1973.
He is a native of the Shetland Islands (Scotland) and has lived and worked in Europe and the USA. During his career he has held a number of leadership positions in Industry Associations and in 2008 he was awarded an Honorary Doctorate in Veterinary Medicine and Surgery by the University of Edinburgh. George is founder and CEO of Stonehaven Consulting AG, he is non-executive Chairman of Nexvet Biopharma Ltd and is a non-executive director of Phibro Animal Health Corporation, Diversigen Inc., and Sidai Africa Ltd.

  • Alan Mackay

    Executive Partner and Founder
    GHO Capital

Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden’s largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor’s degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He currently serves on the board of the BVCA and previously chaired its Responsible Investment Advisory Board.

Linda Rhodes v2
  • Linda Rhodes

    Independent and ex- CSO of Aratana Therapeutics
    Independent and ex- CSO of Aratana Therapeutics

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.

Aaron Schacht - Elanco
  • Aaron Schacht

    Vice President, Global Research and Development
    Elanco Animal Health

Mr. Aaron Schacht is currently the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Health. Prior to this, Mr. Aaron Schacht held a role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.

Jean_Deleforge v2
  • Jean Deleforge

    Chief Scientific Officer

A seasoned healthcare executive involved for 25 years in the management of businesses spanning across diagnostics, vaccines and drugs. Passionnate about bringing clinically valuable innovation to the healthcare market, together with equally passionnate people. Hold executive positions in business development, franchise management, strategic development, portfolio management, Regulatory, Manufacturing, Marketing, Quality and R&D at bioMerieux, Merial and Vetoquinol. Director on the Board of multiple biotech companies (Biocartis, Adiagene, PathoQuest, Knome, Geneuro). DVM, MBA.